Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.

Title: CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
Authors: GHIORZO, PAOLA; BATTISTUZZI, LINDA; BORGONOVO, GIACOMO; BRUNO, WILLIAM; DE CIAN, FRANCO; GARGIULO, SARA; NASTI, SABINA; PASTORINO, LORENZA; SAVARINO, VINCENZO; BIANCHI, GIOVANNA; DULBECCO, PIETRO; MASTRACCI, LUCA; GRILLO, FEDERICA; PAPADIA, FRANCESCO SAVERIO; Fornarini G; Sciallero S; Belli F; Bernard L; Bonelli L; Decensi A; Filauro M; Faravelli F; Gozza A; Mariette F; Queirolo P; Varesco L; Belli, F.; Queirolo, P.; Parodi, C.; Sacchi, G.
Contributors: Ghiorzo, Paola; Fornarini, G; Sciallero, S; Battistuzzi, Linda; Belli, F; Bernard, L; Bonelli, L; Borgonovo, Giacomo; Bruno, William; DE CIAN, Franco; Decensi, A; Filauro, M; Faravelli, F; Gozza, A; Gargiulo, Sara; Mariette, F; Nasti, Sabina; Pastorino, Lorenza; Queirolo, P; Savarino, Vincenzo; Varesco, L; Bianchi, Giovanna; Belli, F.; Dulbecco, Pietro; Mastracci, Luca; Grillo, Federica; Papadia, FRANCESCO SAVERIO; Queirolo, P.; Parodi, C.; Sacchi, G.
Publisher Information: British Medical Association; GBR; Londra
Publication Year: 2012
Collection: Università degli Studi di Genova: CINECA IRIS
Subject Terms: Adult; Aged; 80 and over; Case-Control Studie; Cyclin-Dependent Kinase Inhibitor p16; DNA Mutational Analysi; Female; Gene Frequency; Genes; Neoplasm; Genetic Association Studie; Genetic Predisposition to Disease; Germ-Line Mutation; Human; Italy; Male; Middle Aged; Pancreatic Neoplasm; Genetic; Genetics (clinical)
Description: Background: Most familial pancreatic cancer (FPC) remains unexplained. The identification of individuals with a high genetic risk of developing pancreatic adenocarcinoma (PC) is important to elucidate its biological basis and is critical to better define emerging strategies for the detection of early pancreatic neoplasms. Patients and methods: A series of 225 consecutively enrolled patients with PC were tested for CDKN2A mutations. After personal and family cancer histories of all the patients had been reviewed, a subset of the patients were classified as FPC and were also tested for mutations in PALLD, PALB2, BRCA1 and BRCA2 as FPC candidate genes. Results: The CDKN2A mutation rate in the 225 PC cases was 5.7%. The CDKN2A founder mutations, p.E27X and p.G101W, were predominant, but the mutation spectrum also included p.L65P, p.G67R and two novel, potentially pathogenic variants, promoter variant c.-201ACTC>CTTT and p.R144C. None of the patients with FPC harboured germline mutations in PALLD, PALB2 or BRCA2. One family was positive for the BRCA1 UV variant p.P727L. Strikingly, five of 16 patients with FPC (31%) carried CDKN2A mutations. Conclusion These findings suggest that a sizeable subset of Italian FPC families may carry CDKN2A mutations. This result may be of value for identifying the best candidates for future PC screening trials in Italy.
Document Type: article in journal/newspaper
File Description: STAMPA
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/22368299; info:eu-repo/semantics/altIdentifier/wos/WOS:000300839100003; volume:49(3); firstpage:164; lastpage:170; numberofpages:7; journal:JOURNAL OF MEDICAL GENETICS; https://hdl.handle.net/11567/331041
DOI: 10.1136/jmedgenet-2011-100281
Availability: https://hdl.handle.net/11567/331041; https://doi.org/10.1136/jmedgenet-2011-100281
Accession Number: edsbas.1218E92C
Database: BASE